Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT

Bone Marrow Transplantation volume 55, pages 796–803 (2020)Cite this article

Subjects

Abstract

Systemic anaplastic large cell lymphoma (sALCL) is a rare histological entity expressing the CD30 antigen that comprises around 11% of peripheral T-cell lymphoma. We analysed the outcome of patients with relapsed/refractory sALCL treated with autologous stem cell transplantation (auto-HCT). We included 65 adult patients (42 males; median age, 44 years); 24 patients had an ALK-ve sALCL. Fifty-one patients had chemosensitive disease at the time of transplant. Ten patients (15%) were treated with brentuximab vedotin (BV) before auto-HCT (median number of doses: 5). The median follow-up for surviving patients was 35 months (3–71). Three-year cumulative incidence of nonrelapse mortality and of relapse were 1.7% and 34%, respectively. Three-year progression-free survival and overall survival were 64% and 73%, respectively. No prognostic factors for any of the outcomes analysed were found in univariate analysis. There were no significant differences in any of the outcomes between patients who had received BV and the remainder. This is the largest analysis presented so far analysing the role of auto-HCT in patients with relapsed/refractory sALCL, showing a promising PFS and OS in this high-risk population. The potential impact of the administration of BV as salvage strategy before the procedure needs to be further elucidated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89:3909–18.

    Article  Google Scholar 

  2. Mora J, Filippa DA, Thaler HT, Polyak T, Cranor ML, Wollner N. Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer. 2000;88:186–97.

    Article  CAS  Google Scholar 

  3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebertet R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  CAS  Google Scholar 

  4. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. International peripheral T-Cell lymphoma project. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-Cell lymphoma project. Blood. 2008;111:5496–504.

    Article  CAS  Google Scholar 

  5. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93:2697–706.

    CAS  PubMed  Google Scholar 

  6. Sibon D, Fournier M, Brière J, Lamant L, Coiffier B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol. 2012;30:3939–46.

    Article  Google Scholar 

  7. Parilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–80.

    Article  Google Scholar 

  8. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–25.

    Article  CAS  Google Scholar 

  9. Sibon D, Nguyen D-P, Schmitz N, Suzuki R, Feldman AL, Gressin R, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019 [ahead of print].

  10. Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–40.

    Article  CAS  Google Scholar 

  11. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.

    Article  CAS  Google Scholar 

  12. Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715–23.

    Article  CAS  Google Scholar 

  13. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014;124:1570–7.

    Article  CAS  Google Scholar 

  14. Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;91:672–6.

    Article  CAS  Google Scholar 

  15. Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Schönland S, Luft T, et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018;97:1241–50.

    Article  Google Scholar 

  16. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–8.

    Article  CAS  Google Scholar 

  17. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.

    Article  CAS  Google Scholar 

  18. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.

    Article  Google Scholar 

  19. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750–8.

    Article  CAS  Google Scholar 

  20. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–9.

    Article  Google Scholar 

  21. Morel A, Brière J, Lamant L, Loschi M, Haioun C, Delarue R, et al. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: a LYSA/SFGM-TC study. Eur J Cancer. 2017;83:146–53.

    Article  CAS  Google Scholar 

  22. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6.

    Article  CAS  Google Scholar 

  23. Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, et al. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica. 2017;102:1931–5.

    Article  CAS  Google Scholar 

  24. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709–17.

    Article  CAS  Google Scholar 

  25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  Google Scholar 

  26. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transpl. 2015;50:1037–56.

    Article  CAS  Google Scholar 

  27. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T Cell and NK/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:1826–38.

    Article  Google Scholar 

  28. Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network. J Clin Oncol. 2017;35:2008–17.

    Article  Google Scholar 

  29. Nademanee A, Palmer JM, Popplewell L, Tsai NC, Delioukina M, Gaal K, et al. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. Biol Blood Marrow Transplant. 2011;17:1481–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Hematology Department, Institut Català d’Oncologia, Barcelona, Spain

    E. Domingo-Domènech & A. Sureda

  2. EBMT Paris Study Office, Paris, France

    A. Boumendil & H. Finel

  3. Pathology Department, Hospital Universitari Bellvitge, Barcelona, Spain

    F. Climent

  4. BMT Unit Dept. of Hematology L, 4042, Rigshospitalet, Copenhagen, Denmark

    H. Sengeloev

  5. Hematology Department, Karolinksa University Hospital, Stockholm, Sweden

    B. Wahlin

  6. Haematologie/Onkologie/Stammzelltransplantation, Evangelisches Krankenhaus Essen-Werden, Essen, Germany

    W. Wattad

  7. Hematopoietic SCT Unit, Florence Nightingale Sisli Hospital, Istambul, Turkey

    M. Arat

  8. Department of Hematology, Radboud University-Nijmegen Medical Centre, Nijmegen, The Netherlands

    N. Schapp

  9. Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

    A. Ganser

  10. Hematology and BMT Department, Beilinson Hospital, Petach_Tikva, Israel

    M. Yeshurun

  11. Hematology, Hospital C. Panico, Tricase_Lecce, Italy

    V. Pavone

  12. Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

    J. Snowden

  13. Dept. of Medicine -Hematology, Oncology, University of Freiburg, Freiburg, Germany

    J. Finke

  14. Department of Haemato-oncology, St. Bartholomew’s Hospital, Barts Health NHS Trust, London, UK

    S. Montoto

  15. Medizinische Klinik V, University of Heidelberg, Heidelberg, Germany

    P. Dreger

Authors
  1. E. Domingo-Domènech
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Boumendil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Climent
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Sengeloev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Wahlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Wattad
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Arat
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Finel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N. Schapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Ganser
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Yeshurun
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. V. Pavone
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. Snowden
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J. Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S. Montoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A. Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. P. Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Corresponding author

Correspondence to A. Sureda.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Domingo-Domènech, E., Boumendil, A., Climent, F. et al. Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. Bone Marrow Transplant 55, 796–803 (2020). https://doi.org/10.1038/s41409-019-0734-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0734-7

Search

Advanced search

Quick links